Opinion

Video

Impact of Transplant Eligibility on Treatment Selection

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

Panelists discuss how transplant eligibility significantly influences first-line treatment goals and initial therapy selection in multiple myeloma, often leading to more intensive induction regimens aimed at achieving deep remissions.

Video content above is prompted by the following:

  • How does transplant eligibility impact first-line treatment goals and selection of initial therapy?
Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
Multiple Myeloma is a cancer of plasma cells, a type of white blood cell found in bone marrow - Image credit: kamonrat | stock.adobe.com
November 12th 2024

Bispecific Antibody Receives FDA Orphan Drug Designation for the Treatment of Multiple Myeloma

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Oncology Edition
April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

Image Credit: © CHA - stock.adobe.com
November 6th 2024

Bone Marrow Adipocytes May Offer Early Detection of MGUS Progression to Multiple Myeloma

Alexandra Gerlach, Associate Editor
Image Credit: © Сергей Косилко - stock.adobe.com
November 1st 2024

Carfilzomib, Lenalidomide, and Dexamethasone: A Curative Approach for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Multiple myeloma in bone marrow -- Image credit: Saiful52 | stock.adobe.com
October 24th 2024

Advances in CAR T-Cell Therapy and Bispecifics for Relapsed/Refractory Multiple Myeloma

Alana Hippensteele, Managing Editor
Team of health care professionals -- Image credit: New Africa | stock.adobe.com
October 23rd 2024

The Pharmacist’s Role on the Multiple Myeloma Care Team Can Vary Among Cancer Centers When Treating Patients With Bispecifics

Gillian McGovern, Assistant Editor